Opinion

Video

Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Experts discuss the results of the CORE-001 Trial.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following questions:

      • In the CORE-001 trial, what were the results for the primary endpoint of complete response at 24 months as well as the secondary endpoint of duration of response? What is notable about these results?
      • How do these results compare to those associated with other FDA-approved therapies and other investigational drugs?
      • What was the overall cystectomy-free survival rate, and what was this rate among patients who experienced a complete response?
      • Were there other notable efficacy outcomes?

      Related Videos
      John Taylor, III, MD, on novel options in NMIBC
      John Taylor, III, MD, on novel options in NMIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      What a long-term study of patients undergoing RARC reveals about upstaging
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Sima Porten, MD, on the increased risk of bladder cancer among firefighters
      Jason Hafron, MD, predicts coming advancements in bladder cancer
      Jason Hafron, MD, predicts coming advancements in bladder cancer
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
      Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
      Neeraja Tillu, MD, answers a question during a Zoom video interview
      Neeraja Tillu, MD, discusses predictors of upstaging following RARC for NMIBC
      Investigators highlight real-world data on nadofaragene firadenovec in NMIBC
      Investigators highlight real-world data on nadofaragene firadenovec in NMIBC
      Gopa Iyer, MD, highlights SURF301 trial of TYRA-300 in mUC
      Gopa Iyer, MD, highlights SURF301 trial of TYRA-300 in mUC
      Related Content
      FDA approves durvalumab/chemo for muscle–invasive bladder cancer
      March 28th 2025

      FDA approves durvalumab/chemo for muscle–invasive bladder cancer

      Hannah Clarke
      The approval is supported by results from the phase 3 NIAGARA trial.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC
      March 26th 2025

      Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

      Andrea Necchi, MD Hannah Clarke
      "Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC
      March 25th 2025

      Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC

      Hannah Clarke
      "Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.
      Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC
      March 24th 2025

      Additional NIAGARA data reinforce benefit of perioperative durvalumab in MIBC

      Hannah Clarke
      “The addition of the durvalumab did not make treatment more morbid than chemotherapy alone, and it didn't change or increase the surgical complications you saw in the ward," says James W.F. Catto, MBChB, PhD, FRCS.
      © 2025 MJH Life Sciences

      All rights reserved.